Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
收藏DataCite Commons2026-04-09 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00004870/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple myeloma.
提供机构：
Vivli
创建时间：
2019-09-19
